Get the Stockscreener App
21.43
1.90%
0.36
Artivion Inc stock is traded at $21.43, with a volume of 543.54K.
It is up +1.90% in the last 24 hours and down -5.71% over the past month.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
See More
Previous Close:
$21.07
Open:
$21.31
24h Volume:
543.54K
Relative Volume:
0.87
Market Cap:
$1.04B
Revenue:
$458.69M
Net Income/Loss:
$11.68M
P/E Ratio:
89.22
EPS:
0.2402
Net Cash Flow:
$14.58M
1W Performance:
+2.83%
1M Performance:
-5.71%
6M Performance:
-53.23%
1Y Performance:
-25.27%
1-Day Range:
$21.09
$21.98
1-Week Range:
$19.88
$21.98
52-Week Range:
$19.16
$48.25
Artivion Inc Stock (AORT) Company Profile
Name
Artivion Inc
Sector
Industry
Phone
(770) 419-3355
Address
1655 ROBERTS BOULEVARD N W, KENNESAW
Compare AORT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AORT
Artivion Inc
|
21.43 | 1.02B | 458.69M | 11.68M | 14.58M | 0.2402 |
ABT
Abbott Laboratories
|
89.83 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
309.78 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.96 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
47.06 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.10 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Artivion Inc Stock (AORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Aug-13-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-17-25 | Initiated | Canaccord Genuity | Buy |
| Oct-23-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-22 | Reiterated | Lake Street | Buy |
| Aug-08-22 | Initiated | Lake Street | Buy |
| Mar-03-22 | Initiated | Stifel | Buy |
View All
Artivion Inc Stock (AORT) Latest News
Artivion’s Andrew Green sells $910,738 in company stock - Investing.com UK
Artivion’s Andrew Green sells $910,738 in company stock By Investing.com - Investing.com India
Artivion (AORT) SVP exercises options and sells 44,001 shares under 10b5-1 plan - Stock Titan
Precision Trading with Artivion Inc Com (AORT) Risk Zones - Stock Traders Daily
AORT Q1 2026 Earnings: EPS Misses Estimates as Profitability Pressures EmergeAnalyst Coverage Count - The League of Women Voters of Texas
What Artivion (AORT)'s Strong Q1 Growth But Lowered Guidance Means For Shareholders - Yahoo Finance
Artivion secures FDA approval for NEXUS aortic arch system - MSN
[144] ARTIVION, INC. SEC Filing - Stock Titan
Will Stronger Revenue but Softer Outlook Change Artivion's (AORT) Growth-Quality Narrative? - simplywall.st
Artivion to present at 2026 Truist Securities MedTech Conference with live webcast on June 16 - Pluang
Artivion to Participate in the 2026 Truist Securities MedTech Conference - marketscreener.com
Cardiac surgery company Artivion joins 2026 Truist MedTech conference in Boston - Stock Titan
Artivion (AORT) Stock Forum and Discussion - Moomoo
Artivion (AORT) Q1 2026 Earnings: Revenue Growth of 17.5% Meets Expectations Amid Mixed Industry Results - IndexBox
Q1 Earnings Outperformers: Artivion (NYSE:AORT) And The Rest Of The Medical Devices & SuppliesCardiology, Neurology, Vascular Stocks - Yahoo Finance
Lake Street Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Artivion (AORT) SVP discloses common stock, RSU and option holdings - Stock Titan
Estate move: Artivion (AORT) director moves 6,325 shares into trust - Stock Titan
Artivion, Inc. has exercised option to acquire Endospan Ltd. for approximately $380 million. - marketscreener.com
Artivion Inc. (AORT) Slips 0.76% as Stock Tests Key Support Near $19.85Hull Moving Average - thelegaladvocate.com
Artivion secures FDA approval for NEXUS aortic arch device, weighs Endospan acquisition - MSN
A Quick Look at Today's Ratings for Artivion(AORT.US), With a Forecast Between $36 to $48 - Moomoo
Stifel Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Stifel reiterates Artivion stock rating on surgeon survey results - Investing.com
Stifel reiterates Artivion stock rating on surgeon survey results By Investing.com - Investing.com South Africa
AORT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Artivion (AORT) Earnings Date and Reports 2026 $AORT - MarketBeat
Artivion Inc. (AORT) Holds Near Support as Mild Pullback Tests Recent RangeIchimoku TK Cross - thelegaladvocate.com
Artivion Inc. (AORT) Faces Selling Pressure as Shares Dip Below Key Moving AveragesTechnical Analysis - thelegaladvocate.com
Artivion Q1 earnings call highlights - MSN
AORT News | ARTIVION INC (NYSE:AORT) - ChartMill
Artivion (AORT) Q1 earnings and revenues surpass estimates - MSN
Artivion (AORT) director corrects details of restricted stock award - Stock Titan
Director at Artivion (NYSE: AORT) awarded 7,576 restricted shares - Stock Titan
Artivion Completes Endospan Acquisition, Expands Aortic Arch Portfolio With FDA-Approved NEXUS System - MedTech Intelligence
Artivion (NYSE:AORT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of - Yahoo Finance
Artivion | 4: Statement of changes in beneficial ownership of securities-Director ACKERMAN THOMAS F - Moomoo
Artivion (AORT) director receives 7,850-share stock award, now holds 56,938 - Stock Titan
Artivion Earnings Call Balances Growth With Caution - TipRanks
Artivion closes Endospan buyout to acquire recently approved heart device - MedTech Dive
Artivion Completes Acquisition of Endospan, Secures FDA Approval for NEXUS Aortic Arch System - Minichart
Artivion Bets On Full Aortic Arch Suite After Endospan Deal - Yahoo Finance
Artivion strengthens aortic arch portfolio with $135m Endospan acquisition - MSN
Artivion (AORT) Completes Acquisition of Endospan for Aortic Sol - GuruFocus
Artivion Closes $175 Million Acquisition of Endospan - Moomoo
Artivion Closes $175M Deal for Aortic Arch Maker Endospan - Medical Product Outsourcing
Artivion completes $175M acquisition of Endospan - Investing.com UK
Artivion Inc Stock (AORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
0.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):